Dudediligence.

Immunovant, Inc

IMVTNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$109.1MSep ’24−$111.1MDec ’24−$106.4MMar ’25−$120.6MJun ’25−$126.5MSep ’25−$110.6MDec ’25−$147.9MMar ’26−$153.2MJun ’26
Fiscal years, by the month each ended
LineMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Net income−$156.7M−$211.0M−$259.3M−$413.8M−$505.6M
Operating cash flow−$106.1M−$188.2M−$214.2M−$375.9M−$407.3M
Free cash flow−$106.4M−$188.4M−$214.6M−$376.6M−$407.3M
Cash$493.8M$376.5M$635.4M$714.0M$902.1M
Shares outstanding116.5M130.3M145.6M170.1M203.9M